What is Zymeworks's reportable segment — R&D?

Zymeworks (ZYME) reported reportable segment — R&D of $34.46M in Q1 2026.

What does reportable segment — R&D mean?

This metric aggregates all costs associated with the research and development activities of the reportable segment, including clinical trials, laboratory operations, and platform development. It is a primary measure of the company's commitment to advancing its therapeutic pipeline and innovation engine.

Zymeworks ZYME Reportable Segment — R&D

Similar metrics at other companies

TVTXReportable Segment — R&D

$57.09M+21.8%

INDVReportable Segment — R&D

$16M-27.3%

VCYTReportable Segment — R&D

$27.1M+52.9%

TARSReportable Segment — R&D

$22.35M+55.1%

CRNXReportable Segment — R&D

$100.08M+31.3%

AGIOReportable Segment — R&D

$23.91M+12.1%

Other financials

Income statement

See full

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

See full

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

See full

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

See full

Market cap$1.76B+125%

Enterprise value$1.53B+112%

P/S21.6×+13.2×

Profitability

See full

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

See full

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's reportable segment — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zymeworks's reportable segment — R&D?: Zymeworks (ZYME) reported reportable segment — R&D of $34.46M in Q1 2026.
What does reportable segment — R&D mean?: This metric aggregates all costs associated with the research and development activities of the reportable segment, including clinical trials, laboratory operations, and platform development. It is a primary measure of the company's commitment to advancing its therapeutic pipeline and innovation engine.